Publications by authors named "Jerome Lechedanec"
Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.
Antimicrob Agents Chemother
September 2020
Article Synopsis
- A population pharmacokinetic model was created to investigate how pregnancy affects the levels of unbound raltegravir, an HIV medication, in the body.
- The study involved 43 HIV-positive pregnant women, who were given a specific dosage of raltegravir, with samples taken during the third trimester and after childbirth to analyze drug levels.
- Findings showed that while overall drug absorption decreased during pregnancy, the concentration of unbound raltegravir didn’t significantly drop, suggesting that the drug's effectiveness remains clinically relevant for pregnant women.
The aims of this study were to describe the unbound and total lopinavir (LPV) pharmacokinetics in pregnant women in order to evaluate if a dosing adjustment is necessary during pregnancy. Lopinavir placental transfer is described, and several genetic covariates were tested to explain its variability. A total of 400 maternal, 79 cord blood, and 48 amniotic fluid samples were collected from 208 women for LPV concentration determinations and pharmacokinetics analysis.
View Article and Find Full Text PDF